Treatment of Hypertension in the Institutionalized Elderly
Wilbert S. Aronow MD
From the Hebrew Hospital Home, Bronx, NY, and the Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, NY
Search for more papers by this authorWilbert S. Aronow MD
From the Hebrew Hospital Home, Bronx, NY, and the Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, NY
Search for more papers by this authorAbstract
The goal of antihypertensive therapy in elderly institutionalized persons is to reduce the blood pressure to <140/90 mm Hg if possible. Elderly persons with diastolic hypertension should have their diastolic blood pressure lowered to 80–85 mm Hg. Elderly persons with stage 2 or 3 hypertension, stage 1 hypertension and target organ damage, evidence of clinical cardiovascular disease, or diabetes mellitus should be treated with antihypertensive drug therapy immediately in addition to lifestyle modification. The initial antihypertensive drug in elderly persons without associated medical conditions should be a diuretic or β-blocker because these drugs have been shown to decrease cardiovascular morbidity and mortality in controlled clinical trials. The initial antihypertensive drug in elderly persons should depend on the associated medical condition. If a second antihypertensive drug is indicated, a drug from another class should be administered. If a diuretic is not the initial drug, it is usually indicated as the second drug. If the antihypertensive response is inadequate after reaching the full dose of two classes of drugs, a third drug from another class should be added. Causes of secondary hypertension should be identified and treated.
References
- 1 Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996; 77: 864–866.
- 2 1997 Joint National Committee. The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med. 1997; 157: 2413–2444.
- 3 Mendelson G, Ness J, Aronow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999; 47: 597–599.
- 4 Aronow WS, Ahn C, Kronzon I, et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991; 67: 295–299.
- 5 Aronow WS, Ahn C, Kronzon I, et al. Association of plasma renin activity and echocardiographic left ventricular hypertrophy with frequency of new coronary events and new atherothrombotic brain infarction in older persons with systemic hypertension. Am J Cardiol. 1997; 79: 1543–1545.
- 6 Applegate WB, Rutan GH. Advances in management of hypertension in older persons. JAm Geriatr Soc. 1992; 40:1 164–1174.
- 7 National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program working group report on hypertension in the elderly. Hypertension. 1994; 23: 275–285.
- 8 Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1488 older women. Am J Cardiol. 1996; 77: 1381–1383.
- 9 Aronow WS, Sales FF, Etienne F, et al. Prevalence of peripheral arterial disease and its correlation with risk factors for peripheral arterial disease in elderly patients in a long term health care facility. Am J Cardiol. 1988; 62: 644–646.
- 10 Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998; 113: 867–869.
- 11 Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on Hypertension in Elderly Trial. Lancet. 1985; 1: 1349–1354.
- 12 Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP Hypertension). Lancet. 1991; 338: 1281–1285.
- 13 MRC Working Party. Medical Research Council. Trial of treatment of hypertension in older adults: Principal results. BMJ. 1992; 304: 405–412.
- 14 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255–3264.
- 15 Staessen JA, Fagard R, Thijs L, et al. Randomised double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997; 350: 757–764.
- 16 Aronow WS. Management of older persons after myocardial infarction. J Am Geriatr Soc. 1998; 46: 1459–1468.
- 17 Coope J, Warrender TS. Randomised trial of treatment of hypertension in the elderly in primary care. BMJ. 1986; 293: 1145–1151.
- 18 Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997; 278: 212–216.
- 19 Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE). JAMA. 1998; 279: 839–846.
- 20 Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med. 1993; 329: 1912–1917.
- 21 Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal result of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755–1762.
- 22 Pedersen TR, for the Norwegian Multicentre Study Group. Six year follow up of the Norwegian Multicentre Study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313: 1055–1058.
- 23 Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982; 247: 1707–1714.
- 24 Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥ 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol. 1994; 74: 267–270.
- 25 Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1994; 74: 674–680.
- 26 Aronow WS. Postinfarction use of beta blockers in elderly patients. Drugs Aging. 1997; 6: 424–432.
- 27 Olson HG, Aronow WS. Medical management of stable angina and unstable angina in the elderly with coronary artery disease. In: WS Aronow, DD Tresch (eds). Clinics in Geriatric Medicine-Coronary Artery Disease in the Elderly. Philadelphia: WB Saunders; 1996: 121–140.
- 28 Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an antiischemic than an antiarrhythmic effect. Am J Cardiol. 1994; 74: 613–615.
- 29 Aronow WS. Optimal management of atrial fibrillation in the elderly. Drugs Aging. 1994; 4: 184–193.
- 30 Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992; 327: 669–677.
- 31 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821–828.
- 32 Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995; 332: 80–85.
- 33 Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995; 273: 1450–1456.
- 34 Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993 ; 71: 602–604.
- 35 Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet. 1997; 349: 747–752.
- 36 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334: 1349–1355.
- 37 Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥ 40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol. 1997; 80: 207–209.
- 38 Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A meta analysis of 109 treatment studies. Am J Hypertens. 1992; 5: 95–110.
- 39 Lewis EJ, Hunsicker LG, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329: 1456–1462.
- 40 Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetics with isolated systolic hypertension. JAMA. 1996; 276: 1886–1892.
- 41 Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338: 645–652.
- 42 Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21: 597–603.
- 43 Aronow WS. The heart and thyroid disease. In: S Gambert (ed). Clinics in Geriatric Medicine-Thyroid Disease. Philadelphia: WB Saunders; 1995: 219–229.
- 44 Aronow WS. Cardiovascular drug therapy in the elderly. In: WH Frishman, EH Sonnenblick (eds). Cardiovascular Pharmacotherapeutics. New York, NY: McGraw-Hill, Inc; 1997: 1267–1281.
- 45 Aronow WS, Lee NH, Sales FF, et al. Prevalence of postural hypotension in elderly patients in a long term health care facility. Am J Cardiol. 1988; 62: 336.
- 46 Aronow WS, Ahn C. Postprandial hypotension in 499 elderly persons in a long term health care facility. J Am Geriatr Soc. 1994; 42: 930–932.
- 47 Aronow WS. Dizziness and syncope. In: WR Hazzard, JP Blass, WH Ettinger, et al (eds). Principles of Geriatric Medicine and Gerontology. 4th edition. New York, NY: McGraw-Hill, Inc; 1998: 1519–1534.
- 48 Schoenfeld MR, Aronow WS, Kutcher R, et al. The incidence of atheromatous renovascular disease in the elderly diagnosed by duplex ultrasonography. J Cardiovasc Tech. 1989; 8: 283–286.